First‐generation EGFR‐tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, second‐generation EGFR‐TKI afatinib and dacomitinib, and third‐generation EGFR‐TKI osimertinib are approved as first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with activating EGFR mutations. This evidence concerns the gene EGFR and lung cancer.